IPCA Laboratories raises FY27 guidance on a strong Q1 beat, the clearest positive PHARMA catalyst since the sector's AVOID stance settled into three flat sessions.
IPCA raised FY27 revenue-growth guidance to 14-16% (from 12-13%) and EBITDA margin guidance to 23% (from 22%) after Q1 FY27 revenue grew 21% YoY with margin expanding to 22.88% from 18.39% -- the stock jumped roughly 11-12% to a record high. It's a real, company-specific positive that lines up with today's pending IPCALAB HOLD->QUALITY-WAIT call flip, though PHARMA's AVOID stance reflects sector-wide overhangs (Lupin's US pricing trough, the deferred-but-unresolved generic tariff timeline) that one strong print does not clear.
GIFT Nifty points flat-to-negative into the open despite a strong Wall Street close, with inflation running hotter than the RBI's own forecast.
GIFT Nifty was little changed near 24,331 in early trade, and commentary frames a flat-to-negative Indian open even after the S&P 500 (+0.7%) and Nasdaq (+1.4%) rallied Thursday on Nvidia and Salesforce earnings -- other overnight cues are offsetting the US tailwind. July CPI came in at 4.45%, a 19-month high, running above the RBI's own 5.0% FY27 forecast set at its Aug 5 hold (repo steady at 5.25%, GDP forecast raised to 6.7%). Brent sits near $88/bbl (up ~31% y/y), USD/INR is at a near-record-weak 95.54, and the US Fed remains on hold with 2026 cut odds now essentially gone.
The official index p/e published after The Close went out, and
is included below. The evening report names what it is
still waiting for, so nothing appears without having been declared missing first.
Source: NSE event calendar, filtered to the 1443 tracked names.
Market Overview
Index
Close
Points
Change
P/E
P/B
Nifty 50
24,175.65
▲ +84.80
▲ +0.35%
20.44
2.93
Nifty Next 50
74,159.15
▼ -188.30
▼ -0.25%
19.60
3.30
Nifty 500
23,528.55
▲ +46.55
▲ +0.20%
22.86
3.28
Nifty Bank
57,496.30
▼ -13.65
▼ -0.02%
13.60
1.72
NIFTY Midcap 100
64,069.50
▲ +34.05
▲ +0.05%
30.88
4.43
▲ 1348 advancing■ 38 unchanged▼ 1230 decliningof 2616 equities, vs the 2026-08-27 close
FII/DII cash flows have not published for this session yet — NSE releases them later in the evening, after this report goes out. They appear in tomorrow morning's Open. No figure is shown here rather than the previous session's.
Source: NSE ind_close_all_20260828
(levels, index P/E and P/B) and the full-market bhavcopy (breadth).
Since We Flagged
The desk's track record — the FIRST call made on each standing name,
against its call today. Entry price is the close on the day of that first call, read
from the cached bhavcopy for that date. "Unchanged" means the original call still
stands.
Infosys narrows FY27 guidance even as Q1 large-deal bookings hit $3.6bn, sharpening this season's IT guidance-caution thesis Information Technology
Infosys narrowed its FY27 CC revenue-growth guidance to 1.5%-3.0% on Aug 12 despite Q1 large-deal TCV of $3.6bn (61% net new) and a pipeline described as near two-year highs. It's the clearest single-company confirmation yet of the sector-wide 'guidance caution despite strong bookings' pattern already flagged across HCLTech, TCS and LTIMindtree.
GCPL's leadership transition holds steady two weeks after Sitapati's abrupt exit FMCG
New MD & CEO Aasif Malbari's handover has seen no further senior departures or disclosed governance issues as of this session, following Sudhir Sitapati's abrupt Aug 10-11 resignation days after shareholders approved his reappointment. The falsifier window on that governance-risk question runs to Nov 30.
Deepak Nitrite commits roughly Rs17,500cr to new capex across three projects, capped by a first-of-its-kind Indian polycarbonate-resin platform
Subsidiary Deepak Chem Tech has approved a ~Rs3,500cr Dahej phenol/acetone/IPA project, a ~Rs2,500cr BPA project (Aug 4), and the flagship ~Rs11,000cr polycarbonate-resin ecosystem targeted for 2028, alongside a record Q1 FY27 profit on integration gains from recently commissioned capacity.
Canara Bank's compliance-function head departs without a stated reason Banks
Group Chief Compliance Officer Rakesh Kashyap was relieved of duties effective June 29, 2026, per an exchange disclosure that names no cause -- a single-sourced governance data point worth tracking rather than a confirmed red flag, alongside continued Q1 FY27 asset-quality improvement.
Aurobindo Pharma posts strong Q1 profit growth and completes the Lannett acquisition Pharmaceuticals
Aurobindo's consolidated Q1 FY27 net profit rose roughly 26% YoY to about Rs1,033cr; it also closed its ~$250m acquisition of US-based Lannett and is restructuring step-down subsidiaries. Single-sourced to an aggregator this session -- a real incremental positive, but narrower in reach than IPCA's guidance raise.
Entry score is 40% cheap-vs-history + 25% quality trend + 20% news catalyst + 15% technicals, for the 3 sectors with a researched catalyst. The other 18 show —: no catalyst was researched for them, so their score renormalises over the remaining three inputs rather than assuming a neutral headline. ≥62 accumulate · 45–61 watch · <45 avoid.
Source: data/verdicts.json × NSE sector index closes.
Stocks to Watch
Split across large/mid/small cap so this list isn't one tier's picks —
new calls first, then the highest long-term composites within each.
Each shows the figures that selected it — open the desk for the full six-lens panel.